Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
The future research agenda. A view from the pharmaceutical industry.

PharmacoEconomics

Barr C.
PMID: 10155587
Pharmacoeconomics. 1994;6:61-2. doi: 10.2165/00019053-199400061-00014.

As a responsible partner in healthcare systems, the pharmaceutical industry hopes to see a research agenda on pharmaceutical issues that will provide more information on trends in healthcare reform affecting medicines. Urgent questions include whether some forms of cost...

Cite
Barr C. The future research agenda. A view from the pharmaceutical industry. Pharmacoeconomics. 1994;6:61-2doi: 10.2165/00019053-199400061-00014.
Barr, C. (1994). The future research agenda. A view from the pharmaceutical industry. PharmacoEconomics, 661-2. https://doi.org/10.2165/00019053-199400061-00014
Barr, C. "The future research agenda. A view from the pharmaceutical industry." PharmacoEconomics vol. 6 (1994): 61-2. doi: https://doi.org/10.2165/00019053-199400061-00014
Barr C. The future research agenda. A view from the pharmaceutical industry. Pharmacoeconomics. 1994;6:61-2. doi: 10.2165/00019053-199400061-00014. PMID: 10155587.
Copy Download .nbib Format: NLM
Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence.

Health affairs (Project Hope)

Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO.
PMID: 28373337
Health Aff (Millwood). 2017 Apr 01;36(4):706-713. doi: 10.1377/hlthaff.2016.1213.

Global biopharmaceutical companies are increasingly establishing access-to-medicines (AtM) initiatives in low- and middle-income countries. We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact...

Cite
Rockers PC, Wirtz VJ, Umeh CA, et al. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Health Aff (Millwood). 2017;36(4):706-713doi: 10.1377/hlthaff.2016.1213.
Rockers, P. C., Wirtz, V. J., Umeh, C. A., Swamy, P. M., & Laing, R. O. (2017). Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Health affairs (Project Hope), 36(4), 706-713. https://doi.org/10.1377/hlthaff.2016.1213
Rockers, Peter C, et al. "Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence." Health affairs (Project Hope) vol. 36,4 (2017): 706-713. doi: https://doi.org/10.1377/hlthaff.2016.1213
Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Health Aff (Millwood). 2017 Apr 01;36(4):706-713. doi: 10.1377/hlthaff.2016.1213. PMID: 28373337.
Copy Download .nbib Format: NLM
Health care spending growth at record low in 1996; prescription drugs break pattern with 9% increase.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

[No authors listed]
PMID: 9568237
Am J Health Syst Pharm. 1998 Apr 15;55(8):768. doi: 10.1093/ajhp/55.8.768a.

No abstract available.

Cite
Health care spending growth at record low in 1996; prescription drugs break pattern with 9% increase. Am J Health Syst Pharm. 1998;55(8):768doi: 10.1093/ajhp/55.8.768a.
(1998). Health care spending growth at record low in 1996; prescription drugs break pattern with 9% increase. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 55(8), 768. https://doi.org/10.1093/ajhp/55.8.768a
"Health care spending growth at record low in 1996; prescription drugs break pattern with 9% increase." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol. 55,8 (1998): 768. doi: https://doi.org/10.1093/ajhp/55.8.768a
Health care spending growth at record low in 1996; prescription drugs break pattern with 9% increase. Am J Health Syst Pharm. 1998 Apr 15;55(8):768. doi: 10.1093/ajhp/55.8.768a. PMID: 9568237.
Copy Download .nbib Format: NLM
Rising prescription prices. A tough pill to swallow.

New Jersey medicine : the journal of the Medical Society of New Jersey

Singer RW.
PMID: 12955803
N J Med. 2003 Jul-Aug;100(7):29-30.

No abstract available.

Cite
Singer RW. Rising prescription prices. A tough pill to swallow. N J Med. 2003;100(7):29-30
Singer, R. W. (2003). Rising prescription prices. A tough pill to swallow. New Jersey medicine : the journal of the Medical Society of New Jersey, 100(7), 29-30.
Singer, Robert W. "Rising prescription prices. A tough pill to swallow." New Jersey medicine : the journal of the Medical Society of New Jersey vol. 100,7 (2003): 29-30.
Singer RW. Rising prescription prices. A tough pill to swallow. N J Med. 2003 Jul-Aug;100(7):29-30. PMID: 12955803.
Copy Download .nbib Format: NLM
Price controls seen as key to Europe's drug innovations lag.

Nature reviews. Drug discovery

Mitchell P.
PMID: 17457995
Nat Rev Drug Discov. 2007 Apr;6(4):257-8. doi: 10.1038/nrd2293.

No abstract available.

Cite
Mitchell P. Price controls seen as key to Europe's drug innovations lag. Nat Rev Drug Discov. 2007;6(4):257-8doi: 10.1038/nrd2293.
Mitchell, P. (2007). Price controls seen as key to Europe's drug innovations lag. Nature reviews. Drug discovery, 6(4), 257-8. https://doi.org/10.1038/nrd2293
Mitchell, Peter. "Price controls seen as key to Europe's drug innovations lag." Nature reviews. Drug discovery vol. 6,4 (2007): 257-8. doi: https://doi.org/10.1038/nrd2293
Mitchell P. Price controls seen as key to Europe's drug innovations lag. Nat Rev Drug Discov. 2007 Apr;6(4):257-8. doi: 10.1038/nrd2293. PMID: 17457995.
Copy Download .nbib Format: NLM
The NHS drugs budget: a report by the Commons Select Committee.

Drug and therapeutics bulletin

[No authors listed]
PMID: 7635039
Drug Ther Bull. 1994 Aug 18;32(8):64. doi: 10.1136/dtb.1994.32864.

Last month the House of Commons Select Committee on Health published the results of its inquiry on "whether the measures introduced by the Government to control the NHS drugs budget are leading to more appropriate and cost effective use...

Cite
The NHS drugs budget: a report by the Commons Select Committee. Drug Ther Bull. 1994;32(8):64doi: 10.1136/dtb.1994.32864.
(1994). The NHS drugs budget: a report by the Commons Select Committee. Drug and therapeutics bulletin, 32(8), 64. https://doi.org/10.1136/dtb.1994.32864
"The NHS drugs budget: a report by the Commons Select Committee." Drug and therapeutics bulletin vol. 32,8 (1994): 64. doi: https://doi.org/10.1136/dtb.1994.32864
The NHS drugs budget: a report by the Commons Select Committee. Drug Ther Bull. 1994 Aug 18;32(8):64. doi: 10.1136/dtb.1994.32864. PMID: 7635039.
Copy Download .nbib Format: NLM
Costs for traditional meds static while specialty drug costs soar.

Managed care (Langhorne, Pa.)

[No authors listed]
PMID: 22792564
Manag Care. 2012 Jun;21(6):47.

No abstract available.

Cite
Costs for traditional meds static while specialty drug costs soar. Manag Care. 2012;21(6):47
(2012). Costs for traditional meds static while specialty drug costs soar. Managed care (Langhorne, Pa.), 21(6), 47.
"Costs for traditional meds static while specialty drug costs soar." Managed care (Langhorne, Pa.) vol. 21,6 (2012): 47.
Costs for traditional meds static while specialty drug costs soar. Manag Care. 2012 Jun;21(6):47. PMID: 22792564.
Copy Download .nbib Format: NLM
The level of income appears to have no consistent bearing on pharmaceutical prices across countries.

Health affairs (Project Hope)

Morel CM, McGuire A, Mossialos E.
PMID: 21821572
Health Aff (Millwood). 2011 Aug;30(8):1545-52. doi: 10.1377/hlthaff.2010.0317.

A generally accepted view is that it is more efficient and ethical if global pharmaceutical prices vary according to countries' relative income. To understand manufacturers' pricing strategies, we compared average pharmaceutical prices in fourteen middle-income countries to those in...

Cite
Morel CM, McGuire A, Mossialos E. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff (Millwood). 2011;30(8):1545-52doi: 10.1377/hlthaff.2010.0317.
Morel, C. M., McGuire, A., & Mossialos, E. (2011). The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health affairs (Project Hope), 30(8), 1545-52. https://doi.org/10.1377/hlthaff.2010.0317
Morel, Chantal M, et al. "The level of income appears to have no consistent bearing on pharmaceutical prices across countries." Health affairs (Project Hope) vol. 30,8 (2011): 1545-52. doi: https://doi.org/10.1377/hlthaff.2010.0317
Morel CM, McGuire A, Mossialos E. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff (Millwood). 2011 Aug;30(8):1545-52. doi: 10.1377/hlthaff.2010.0317. PMID: 21821572.
Copy Download .nbib Format: NLM
AMCP Partnership Forum: Helping patients anticipate and manage drug costs.

Journal of managed care & specialty pharmacy

[No authors listed]
PMID: 33283615
J Manag Care Spec Pharm. 2021 Jan;27(1):127-132. doi: 10.18553/jmcp.2020.20239. Epub 2020 Dec 07.

Prescription drug spending has been rising in recent years and is expected to continue to grow over the next decade. As such, concerns regarding patient affordability and access are areas of focus across the health care industry. In response...

Cite
AMCP Partnership Forum: Helping patients anticipate and manage drug costs. J Manag Care Spec Pharm. 2020;27(1):127-132doi: 10.18553/jmcp.2020.20239.
(2021). AMCP Partnership Forum: Helping patients anticipate and manage drug costs. Journal of managed care & specialty pharmacy, 27(1), 127-132. https://doi.org/10.18553/jmcp.2020.20239
"AMCP Partnership Forum: Helping patients anticipate and manage drug costs." Journal of managed care & specialty pharmacy vol. 27,1 (2021): 127-132. doi: https://doi.org/10.18553/jmcp.2020.20239
AMCP Partnership Forum: Helping patients anticipate and manage drug costs. J Manag Care Spec Pharm. 2021 Jan;27(1):127-132. doi: 10.18553/jmcp.2020.20239. Epub 2020 Dec 07. PMID: 33283615.
Copy Download .nbib Format: NLM
NHS spent 8% more on medicines last year.

BMJ (Clinical research ed.)

Torjesen I.
PMID: 27881369
BMJ. 2016 Nov 22;355:i6320. doi: 10.1136/bmj.i6320.

No abstract available.

Cite
Torjesen I. NHS spent 8% more on medicines last year. BMJ. 2016;355:i6320doi: 10.1136/bmj.i6320.
Torjesen, I. (2016). NHS spent 8% more on medicines last year. BMJ (Clinical research ed.), 355i6320. https://doi.org/10.1136/bmj.i6320
Torjesen, Ingrid. "NHS spent 8% more on medicines last year." BMJ (Clinical research ed.) vol. 355 (2016): i6320. doi: https://doi.org/10.1136/bmj.i6320
Torjesen I. NHS spent 8% more on medicines last year. BMJ. 2016 Nov 22;355:i6320. doi: 10.1136/bmj.i6320. PMID: 27881369.
Copy Download .nbib Format: NLM
Seven therapeutic categories account for most drug cost increases.

Managed care (Langhorne, Pa.)

[No authors listed]
PMID: 22259880
Manag Care. 2011 Dec;20(12):69.

No abstract available.

Cite
Seven therapeutic categories account for most drug cost increases. Manag Care. 2011;20(12):69
(2011). Seven therapeutic categories account for most drug cost increases. Managed care (Langhorne, Pa.), 20(12), 69.
"Seven therapeutic categories account for most drug cost increases." Managed care (Langhorne, Pa.) vol. 20,12 (2011): 69.
Seven therapeutic categories account for most drug cost increases. Manag Care. 2011 Dec;20(12):69. PMID: 22259880.
Copy Download .nbib Format: NLM
Drug bill cuts force firms overseas.

Nature biotechnology

Saegusa A.
PMID: 9624670
Nat Biotechnol. 1998 Jun;16(6):506-7. doi: 10.1038/nbt0698-506b.

No abstract available.

Cite
Saegusa A. Drug bill cuts force firms overseas. Nat Biotechnol. 1998;16(6):506-7doi: 10.1038/nbt0698-506b.
Saegusa, A. (1998). Drug bill cuts force firms overseas. Nature biotechnology, 16(6), 506-7. https://doi.org/10.1038/nbt0698-506b
Saegusa, A. "Drug bill cuts force firms overseas." Nature biotechnology vol. 16,6 (1998): 506-7. doi: https://doi.org/10.1038/nbt0698-506b
Saegusa A. Drug bill cuts force firms overseas. Nat Biotechnol. 1998 Jun;16(6):506-7. doi: 10.1038/nbt0698-506b. PMID: 9624670.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries